NASDAQ: LFWDLifeward Ltd Stock
$0.62+0.00 (+0%)
Updated Aug 28, 2025
LFWD Price
$0.62
Fair Value Price
N/A
Market Cap
$9.74M
52 Week Low
$0.50
52 Week High
$4.00
P/E
-0.2x
P/B
0.64x
P/S
0.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.43M
Earnings
-$29.76M
Gross Margin
35.6%
Operating Margin
-121.63%
Profit Margin
-121.8%
Debt to Equity
0.77
Operating Cash Flow
-$18M
Beta
0.94
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LFWD Overview
Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. Its products include ReWalk Exo-Suit and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Marlborough, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LFWD's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important LFWD news, forecast changes, insider trades & much more!
LFWD News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LFWD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LFWD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LFWD is good value based on its book value relative to its share price (0.64x), compared to the US Medical Devices industry average (4.04x)
P/B vs Industry Valuation
LFWD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LFWD due diligence checks available for Premium users.
Valuation
LFWD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
32.11x
Market
35.78x
LFWD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.64x
Industry
4.04x
LFWD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LFWD's financial health
Profit margin
Revenue
$5.7M
Net Income
-$6.6M
Profit Margin
-114.6%
LFWD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LFWD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.8M
Liabilities
$11.7M
Debt to equity
0.77
LFWD's short-term assets ($20.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LFWD's short-term assets ($20.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LFWD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LFWD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
$0.0
Financing
$3.3M
LFWD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LFWD vs Medical Device Stocks
Lifeward Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.